mono-O-demethyltetrahydrocurcumin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: mono-O-demethyltetrahydrocurcumin
• 英文别名: demethyl-tetrahydrocurcumin；tetrahydrodemethylcurcumin；1-(3,4-dihydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione
• 化学式: C₂₀H₂₂O₆
• 分子量: 358.391
• InChiKey: ABDNUFVBMDRYEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  去甲基姜黄素 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以62%的产率得到mono-O-demethyltetrahydrocurcumin
  参考文献：
  名称：

  姜黄素衍生物的用途

  摘要：

  本发明提供了姜黄素衍生物的用途。具体提供了式Ⅰ所示姜黄衍生物，或其盐在制备抗炎性疾病的药物和/或COX抑制剂的用途。本发明姜黄素衍生物具有良好COX抑制活性和抗炎活性，可用于制备COX抑制剂和抗炎药物。其中，化合物6和化合物7对于COX‑2抑制活性和抗炎活性的效果最优。可用于制备COX‑2抑制剂和抗炎药物。

  公开号：

  CN110327315A

文献信息

• ORALLY ACTIVE CURCUMINOID COMPOUNDS
  申请人：Chaniyilparampu Ramchand Nanappan

  公开号：US20110112190A1

  公开（公告）日：2011-05-12

  The invention discloses a compound of formula (I) wherein, at least one of R 1 , R 2 , R 3 and R 4 is —C(═O)R n and R 1 , R 2 R 3 and R 4 are H or CH 3 and R n is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In R n , where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds.

  本发明公开了一种化合物，其化学式为(I)，其中，R1，R2，R3和R4中至少一个为—C(═O)Rn，且R1，R2，R3和R4为H或CH3，Rn为烷基或烯基基团。烯基基团具有一个或多个双键，可以是顺式或反式，或两者都有。在Rn中，n为12到30个碳；以及其药学上可接受的盐。所述烯基基团优选选自二十碳五烯酸（EPA）或二十二碳六烯酸（DHA）的群。本发明还公开了制备化合物I的方法和含有这些化合物的药物组合物。
• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species
  作者：Chatchawan Changtam、Harry P. de Koning、Hasan Ibrahim、M. Sohail Sajid、Matthew K. Gould、Apichart Suksamrarn

  DOI：10.1016/j.ejmech.2009.11.035

  日期：2010.3

  The natural curcuminoids curcumin (1), demethoxycurcumin (2) and bisdemethoxycurcumin (3) have been chemically modified to give 46 analogs and 8 pairs of 1: 1 mixture of curcuminoid analogs and these parent curcuminoids and their analogs were assessed against protozoa of the Tryponosoma and Leishmania species. The parent curcuminoids exhibited low antitrypanosomal activity (EC50 for our drug-sensitive Trypanosoma brucei brucei line (WT) of compounds 1, 2 and 3 are 2.5, 4.6 and 7.7 mu M, respectively). Among 43 curcuminoid analogs and 8 pairs of 1: 1 mixture of curcuminoid analogs tested, 8 pure analogs and 5 isomeric mixtures of analogs exhibited high antitrypanosomal activity in sub-micromolar order of magnitude. Among these highly active analogs, 1,7-bis(4-hydroxy-3-methoxy-phenyl)hept-4-en-3-one (40) was the most active compound, with an EC50 value of 0.053 +/- 0.007 mu M; it was about 2-fold more active than the standard veterinary drug diminazene aceturate (EC50 0.12 +/- 0.01 mu M). Using a previously characterized diminazene-resistant T. b, brucei (TbAT1-KO) and a derived multi-drug resistant line (B48), no cross-resistance of curcuminoids was observed to the diamidine and melaminophenyl arsenical drugs that are the current treatments. Indeed, curcuminoids carrying a conjugated keto (enone) motif, including 40, were significantly more active against 7: b. brucei B48. This enone motif was found to contribute to particularly high trypanocidal activity against all Trypanosoma species and strains tested. The parent curcuminoids showed low antileishmanial activity (EC50 values of compounds 1 and 2 for Leishmania mexicana amastigotes are 16 +/- 3 and 37 +/- 6 mu M. respectively) while the control drug, pentamidine, displayed an EC50 of 16 +/- 2 mu M. Among the active curcuminoid analogs, four Compounds exhibited EC50 values of less than 5 mu M against Leishmania major promastigotes and four against L mexicana amastigotes. No significant difference in sensitivity to curcuminoids between L. major promastigotes and L. mexicana amastigotes was observed. The parent curcuminoids and most of their analogs were also tested for their toxicity against human embryonic kidney (HEK) cells. All the curcuminoids exhibited lower toxicity to HEK cells than to T b. brucei bloodstream forms and only one of the tested compounds showed significantly higher activity against HEK cells than curcumin (1). The selectivity index for T b. brucei ranged from 3-fold to 1500-fold. The selectivity index for the most active analog, the enone 40, was 453-fold. (C) 2009 Elsevier Masson SAS. All rights reserved.
• WO2007/43058
  申请人：——

  公开号：——

  公开（公告）日：——
• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16